Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.
Saved in:
| Title: | Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. |
|---|---|
| Authors: | Cortes, Jorge E.1 (AUTHOR) jorge.cortes@augusta.edu, Roboz, Gail J.2 (AUTHOR), Baer, Maria R.3 (AUTHOR), Jonas, Brian A.4 (AUTHOR), Schiller, Gary J.5 (AUTHOR), Yee, Karen6 (AUTHOR), Ferrell, P. Brent7 (AUTHOR), Yang, Jay8 (AUTHOR), Wang, Eunice S.9 (AUTHOR), Blum, William G.10 (AUTHOR), Mims, Alice11 (AUTHOR), Tian, Hua12 (AUTHOR), Sheppard, Aaron12 (AUTHOR), de Botton, Stéphane13 (AUTHOR), Montesinos, Pau14 (AUTHOR), Curti, Antonio15 (AUTHOR), Watts, Justin M.16 (AUTHOR) |
| Source: | Journal of Hematology & Oncology. 1/16/2025, Vol. 18 Issue 1, p1-13. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17568722 |
|---|---|
| DOI: | 10.1186/s13045-024-01657-z |
